Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dasatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Xspray Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Xspray Pharma Signs License Agreement with Handa Therapeutics
Details : Xspray granted Handa a non-exclusive license to certain Xspray patents for the commercialization of Handa’s Phyrago (dasatinib) product in the U.S. and, in the future, selected Asian markets.
Product Name : Phyrago
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 12, 2025
Lead Product(s) : Dasatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Xspray Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Dasatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Nanocopoeia
Deal Size : Undisclosed
Deal Type : Acquisition
Handa Acquires FDA-Approved PHYRAGO (dasatinib) Tablets for CML
Details : Handa Therapeutics has acquired Phyrago (dasatinib) from Nanocopoeia. This FDA-approved product is indicated for treating Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia.
Product Name : Phyrago
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 15, 2025
Lead Product(s) : Dasatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Nanocopoeia
Deal Size : Undisclosed
Deal Type : Acquisition